IMP3 signatures of fallopian tube: a risk for pelvic serous cancers by Yiying Wang et al.
JOURNAL OF HEMATOLOGY
& ONCOLOGY
Wang et al. Journal of Hematology & Oncology 2014, 7:49
http://www.jhoonline.org/content/1/1/49SHORT REPORT Open AccessIMP3 signatures of fallopian tube: a risk for pelvic
serous cancers
Yiying Wang1,2, Yue Wang1,2, Dake Li2,3, Lingmin Li2,4, Wenjing Zhang2,5, Guang Yao6,7, Zhong Jiang9
and Wenxin Zheng2,4,6,8*Abstract
Background: Recent advances suggest fallopian tube as the main cellular source for women’s pelvic serous carcinoma
(PSC). In addition to TP53 mutations, many other genetic changes are involved in pelvic serous carcinogenesis. IMP3 is
an oncofetal protein which has recently been observed to be overexpressed in benign-looking tubal epithelia. Such
findings prompted us to examine the relationship between IMP3 over-expression, patient age and the likelihood of
development of PSC.
Methods: Fallopian tubes from three groups (low-risk, high-risk, and PSC) of patients with matched ages were studied.
Age was recorded in 10 years intervals ranging from age 20 to older than 80. The number of IMP3 signatures (defined
by 10 or more tubal secretory cells stained positively and continuously in benign appearing tubal mucosa) from both
tubal fimbria and ampulla segments was measured. The data was analyzed by standard contingency table and Poisson
distribution methods after age adjustment. IMP3 overexpression was also examined in serous tubal intraepithelial
carcinoma and PSC.
Results: The positive IMP3-stained cells are mainly tubal secretory cells. The absolute number of tubal IMP3 signatures
increased significantly within each age group. Age remained a significant risk factor for serous neoplasia after age
adjustment. IMP3 signatures were more frequent in the patients of both high-risk and PSC groups. The presence of
IMP3 signatures in tubal mucosa was significantly associated with tubal or pelvic serous carcinogenesis (p < 0.001).
Conclusions: The findings suggest that tubal secretory cells with IMP3 signatures showing growth advantage could
potentially serve as a latent precancer biomarker for tubal or pelvic serous carcinomas in women.
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The number of tubal IMP3 signatures increased with age,
which served as a significant risk factor for serous neoplasia.
Identification of IMP3 signatures in tubal mucosa was asso-
ciated with tubal or pelvic serous carcinogenesis (p < 0.001).
Introduction
Pelvic serous carcinoma (PSC), including serous cancers
of the ovary, peritoneum, and fallopian tube, is the most
common and lethal type of mullerian malignancy, com-
prising more than 70% of all malignancies from these* Correspondence: zhengw@email.arizona.edu
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majority cases present clinically in advanced stages. There-
fore, investigators have emphasized the importance of
understanding early phases of this disease, including pre-
cancer and latent precancer conditions [4-6]. Important
advances in recent years suggest that precancerous lesions
of PSC originate from the fallopian tube, rather than the
ovary or peritoneal surface [2,7-12]. Within the fallopian
tubal mucosa, there are two different cell types, ciliated
and non-ciliated cells. The latter are also called secretory
cells. It is the secretory cell which serves as the cell of
origin for the majority of PSC [2,7,8,13-15]. A proposed
model for pelvic serous carcinogenesis starts with an in-
creased secretory to ciliated cell ratio within the fallopian
tube epithelia and subsequent loss of TP53 function and
emergence of tubal epithelial “p53 signature”, which istd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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terations of p53 expression [15-17]. This latent pre-
cancer shares attributes with women’s PSC and has been
demonstrated to exist in anatomic continuity with serous
tubal intraepithelial carcinoma (STIC), the earliest mor-
phologically identified form of serous carcinoma within
the pelvis [18-21].
With confidence that tubal secretory cells are the origin
of pelvic HGSC, many investigators have focused their at-
tention on this particular group of cells within the tubal
epithelia. Tubal secretory cell outgrowths (SCOUTs), de-
fined at the cellular level as non-interrupted growth of
at least 30 secretory cells, was the first term defined by
Crum et al. [13]. More recently, we have re-examined the
issue and found secretory cell expansion (SCE), defined
as ≥ 10 secretory cells in a row, is a more sensitive bio-
marker than SCOUTs for pelvic serous carcinogenesis
[15]. This was supported by the observation that SCEs
were found in a significantly higher frequency in tubal
mucosa from patients with high-risk of development
of PSC [15]. Morphologically, SCEs are visible under
light microscope and, therefore, may be used as a reliable
surrogate biomarker for PSC screening and potential
cancer prevention. However, the molecular mechanisms
leading the SCEs to the development of PSC remain
largely unclear.
IMP3, an oncofetal protein, is a member of insulin-like
growth factor II mRNA binding proteins, also known as
IGF2BP3 [22,23]. IMP3 is epigenetically silenced soon
after birth, with little or no detectable protein in normal
adult tissues [24] except in placentas, germinal centers
in lymph nodes, and gonads [25]. Re-activation of IMP3
expression is observed in many human cancers, including
the ovary, the endometrium, and the cervix, correlating
with increased risk of metastases and decreased survival
[24,26-30]. Not only overexpressed in the invasive cancers,
IMP3 has also been considered as a marker of preinvasive
lesions in the cervix and the endometrium [26,28,31].
IMP3 has also been used as a prognostic marker for all
ovarian cancer patients in our routine pathology practice,
during which IMP3 overexpression was sometimes ob-
served in normal-appearing tubal mucosa as well as in
STIC cases. We defined positive IMP3 cytoplasmic stain-
ing in more than 10 tubal epithelial cells in a continuous
fashion as an IMP3 signature. The finding of IMP3 signa-
tures in benign-appearing tubal epithelia and the IMP3
overexpression in STIC and PSC cases prompted us to
examine the following questions: 1) whether IMP3 expres-
sion signifies an early form of tubal serous neoplasia;
2) what the relationship is between IMP3 and tubal SCE
in the process of pelvic serous carcinogenesis; 3) to what
extent the changes are in the IMP3 expression in high-
risk patients as well as patients with PSC; and 4) whether
these changes are independent of the ageing process.Materials and methods
Case collection
A total of 316 consecutively identified surgical cases
including salpingectomy specimens between 2006 and
2013 were identified from pathology files of University of
Arizona Medical Center in Tucson, Arizona. The study
was approved by the institutional review board. Cases
were divided into three groups of patients: low-risk (n =
196), high-risk (n = 60), and patients with PSC (n = 60).
Low-risk patients served as the control group and
consisted of those patients post hysterectomies and sal-
pingectomies performed for benign diseases (leiomyomata,
endometriosis or uterine prolapse). Controls were further
divided into age groups of 10 year intervals to determine
normal distribution of IMP3 signatures. The main reason
to include more control subjects for the study was to
examine if age is related to the increased incidence of
IMP3 signatures. High-risk patients were those with either
BRCA mutations (n = 16), history of breast cancer (n = 32)
or first degree family history of ovarian cancer (n = 12).
Typically, these patients underwent prophylactic bilat-
eral salpingo-oophorectomy. The median and mean
interval between previous breast cancer and prophylactic
bilateral salpingo-oophorectomy were 78 and 85 months,
respectively. The 60 PSC patients represented FIGO stage
2 (n = 5), stage 3 (n = 51) and stage 4 (n = 4). By conven-
tion, the primary sites for these PSC cases included ovary
(n = 50), fallopian tube (n = 4), and peritoneum (n = 6).
Age of patients was matched among the three groups.
For controls, two representative sections of the fallopian
tube, one from ampulla (proximal) and the other from
fimbria were submitted.Tissue handling
For high-risk and PSC groups, the entire fallopian tube
was submitted based on SEE-FIM protocol [2,32]. Fallo-
pian tube from low-risk control cases were processed by
embedding all fimbriated ends similar to cancer patients
with additional representative 2 cross sections of the am-
pulla as described elsewhere [7].Morphologic analysis
The secretory and ciliated cells within the tubal mu-
cosa were readily identifiable under light microscopy.
SCEs and SCOUTs were identified under light micros-
copy and stained with PAX8 and tubulin when morpho-
logic identification was uncertain as described previously
[15]. STIC is a noninvasive carcinoma confined to the
epithelial cells of tubal mucosae and characterized by
significant cytologic atypia and/or atypical intraepithe-
lial proliferation. The diagnosis of STIC and PSC was
confirmed by at least 2 pathologist co-authors as de-
scribed previously [15,21,32,33].
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IMP3 antibody (L523S) was provided by Dako Corporation
(Seattle, WA), which was mouse monoclonal antibody spe-
cific for IMP3/KOC antigen. Immunohistochemical stains
were performed on 5-μm formalin fixed paraffin embedded
tissue sections from representative blocks using the
purified mouse anti-IMP3 antibody and the standard
avidin-biotin-complex technique as described previously
[28-30,34]. Representative sections of endometrial serous
carcinoma served as positive controls for the IMP3 anti-
body [28]. Negative controls were performed by replacing
the primary antibody with non-specific IgG. All slides
were reviewed independently by 2 investigators (YW and
WZ). The percentage of neoplastic cells and nonneoplas-
tic tissues that showed dark brown cytoplasmic staining
was recorded. The intensity of the IHC staining was re-
corded as absent, weak, moderate, or strong. IMP3 over-
expression in STIC or PSC was defined as >10% of the
stained cancer cells with strong intensity of the cytoplas-
mic staining. PAX8 has been considered as a mullerian
epithelial marker identifying tubal secretory, but not cili-
ated cells, α-Tubulin has been used to mark cellular sur-
face cilia [7,14].
Data evaluation and statistical analysis
The presence of IMP3 signatures was defined by 10 or
more tubal secretory cells stained positively and continu-
ously in benign appearing tubal mucosa. The following
parameters were calculated for the cases studied: 1) the
number of IMP3 signatures and their distribution (fim-
bria vs ampulla) were calculated according to age inter-
vals; 2) the comparison of IMP3 signatures in ampulla
and fimbria within the fallopian tube; 3) the frequency of
IMP3 signatures in cases and controls; 4) the frequency
of IMP3 signatures in STIC in cases and controls after
correcting for age; and 5) the IMP3 overexpression in
STIC and PSC.
The data were analyzed by standard contingency table
methods and nonparametric Mann–Whitney U-tests
using the Eproliferative index LOG (Epicenter Software,
Pasadena, CA, USA) and Stat View computer programs.
To adjust age differences and the varying numbers of
section or microscopic fields examined for each case, the
data were calculated on the assumption that the number
of IMP3 signatures in each case follows a Poisson distri-
bution, which is commonly used to model count data,
with an offset term used to account for the microscopic
fields examined.
Results
The incidence of IMP3 signatures increased with age
Cells with IMP3 signature represented tubal secretory
cells. They were confirmed by both morphologic and
immunohistochemcial stainings by PAX8 and tubulin asdescribed previously [15]. There were a significantly in-
creased number of IMP3 signatures in the fallopian tube
with increasing age in all three groups (low-risk, high-
risk, and PSC). This is consistent with our previous find-
ing that secretory cells increase with age accompanied
by decreased ciliated cells [7]. Within the low-risk group,
the IMP3 signatures were not observed in patients under
age 50, but the number of IMP3 signatures increased
significantly in the fallopian tube in higher-age patients.
Within the high-risk group, 5 IMP3 signatures appeared
in the age group of 30–39, then the number of IMP3 sig-
natures increased by approximately 20-fold in age group
70–79. A similar finding to IMP3 signature was found in
the PSC group. Overall, the trend of increasing IMP3 sig-
natures with age was statistically significant (p < 0.001)
within all three groups.
Regarding the tubal locations of IMP3 signatures, within
the high-risk and PSC groups, the tubal fimbria had
about 10-fold more IMP3 signatures than that in the am-
pulla region (p < 0.001). We observed significantly higher
number of IMP3 signatures in the fimbria region from
the patients of low-risk group. The detailed data about
the IMP3 signatures in tubal segments are summarized
in Table 1 and the corresponding bar graph is shown
in Figure 1.
IMP3 signatures were largely correlated with secretory cell
expansions, but not with secretory cell outgrowth
IMP3 positive tubal epithelial cells ranged from a couple of
sporadic tubal epithelial cells to more than 30 epithelial
cells in a row (Figure 2). Based on the positively IMP3-
stained epithelial cells in tubal mucosal segment, we corre-
lated them to the SCE and SCOUTs based on morphologic
and immunophenotypic features of secretory and ciliated
cells and the number of secretory cells in a row. After
excluding focal staining without qualification of IMP3
signatures, we identified a total of 473 foci of IMP3 signa-
tures in the 316 studied cases. Among them, the number
of IMP3 signatures was present in 25 (average of 0.13),
248 (average of 4.13), and 200 (average of 3.33) foci per
group cases in the low-risk, high-risk, and PSC group,
respectively. This suggests that the number of IMP3 sig-
natures per case was approximately 32 and 26 fold higher
in high-risk and PSC group, correspondingly than those
in the low-risk group (p < 0.000). Among the all IMP3
signatures, 388 (82%) corresponded to those morpho-
logically identified SCE, termed as IMP3-SCE, while 85
(18%) represented SCOUTs, termed as IMP3-SCOUTs
(p < 0.01). Representative pictures of IMP3 staining cor-
relating to SCE and SCOUTs are presented in Figure 2.
There were no single IMP3-SCOUTs present in the
low-risk group; all of the 85 IMP3-SCOUTs foci were
distributed in high-risk group (39, 46%) and PSC group
(46, 54%) (p = 0.09).




Low risk (n = 196) High risk (n = 60) #IMP3-S/Group PSC (n = 60)
fimbria ampulla fimbria ampulla fimbria ampulla
20–29 (25 ± 1.9) 0.00 0.00 0.00 0.00 - -
30–39 (34 ± 1.8) 0.00 0.00 5 0.00 - -
40–49 (46 ± 1.8) 0.00 0.00 18 0.00 6 0.00
50–59 (55 ± 1.6) 2 0.00 33 3 28 0.00
60–69 (63 ± 2.2) 4 0.00 74 8 50 3
70–79 (76 ± 1.4) 11 0.00 96 11 76 8
>80 (84 ± 2.3) 8 0.00 - - 24 5
Total 25 0.00 226 22 184 16
PSC: pelvic serous carcinoma. #IMP3-S: the number of IMP3 signatures.
There was no high risk cases with age elder than 80 and no PSC cases younger than 40 in this study. There were only 5 PSC cases with age elder than 80.
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fimbria of patients with high-risk or pelvic serous carcinoma
IMP3 signatures were compared between the case and con-
trol groups in an age matched fashion. The IMP3 signa-
tures significantly increased in tubal segments in patients of
high-risk and PSC groups. Compared with low-risk group,
the number of IMP3 signatures in tubal segments dramat-
ically increased with a total of 248 foci (9.9-fold increment)
in high-risk group and a total of 200 microscopic foci
(8-fold more) in PSC patients (p < 0.001). The IMP3 sig-
natures were noted to be significantly higher in fimbria
(226 foci) than in ampullae (22 foci) region (p < 0.001) in
the high-risk group. However, IMP3 signatures observed
in high-risk and PSC patients showed no statistically sig-
nificant differences (Table 1).
IMP3 signature increment was independently associated with
age, high-risk factors, and the status of pelvic serous carcinoma
Noting that the increased number of tubal IMP3 signa-
tures is associated with age and more frequent in high-Figure 1 The IMP3 signature increases with age. The detailed data arerisk and PSC patients, we explored whether the increased
number of IMP3 signatures in high-risk or PSC patients
are independent of age. We addressed this question in a
regression model that adjusted for age by linear regression
analysis. The three groups (low-risk, high-risk, and PSC)
of patients were divided according to 10-year intervals
and average IMP3 signature frequencies for the intervals
were compared. There were still significant differences in
the increased IMP3 signatures between the case and con-
trol groups independent of the effects of increasing age
(Table 2). When both the cases and controls were com-
bined to provide a greater number for comparison, a sig-
nificant correlation was observed with a determination
coefficient of 0.153, which implies that only about 15% of
the increase in IMP3 signatures could be attributed to
age. Both the high-risk and PSC groups registered higher
IMP3 signatures than low-risk controls (p < 0.001), with
an average increase of 0.85 log counts for high-risk cases
vs control and 0.87 log for PSC cases vs control. There-
fore, IMP3 signatures are seen in increased frequency inpresented in Table 1.
Figure 2 IMP3 signatures in fallopian tube. These tubal sections were derived from high-risk group (a), (b), PSC (c), (e), (f), and low-risk group
(d). Panel (b) shows IMP3 signatures (arrow) in the low-mid area and the corresponding H&E staining shows morphologically unremarkable tubal
epithelial cells (a). Panel (d) shows sporadic cytoplasmic staining of IMP3 in a non-continuous pattern, which is not qualified as IMP3 signatures.
Panel (c) shows multiple foci of IMP3 signatures with some corresponding to IMP3-SCE (single arrow, 10–30 positive cells in a row) and some
corresponding to IMP3-SCOUTs (double arrow, ≥30 positive cells), which are magnified into panel (e) and panel (f), respectively.
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tients with known PSC.
IMP3 signatures and serous tubal intraepithelial carcinoma
were significantly more frequent in tubal segments of
patients with high-risk or pelvic serous carcinoma
As previously defined, IMP3 signatures contain 10 or more
secretory cells in a continuous fashion. IMP3 staining
is most frequently observed in secretory cells since the
majority of IMP3 signatures tubal segments showed homo-
geneous staining of a linear contiguous population of
PAX8-positive cells (secretory cell marker) lacking the dis-
tinctive tubulin (ciliated cell marker) expression (data not
shown). Considering the overall number of STIC is much
less than IMP3 signatures, we calculated the frequency ofTable 2 IMP3 signatures in cases and controls and IMP3 over
pelvic serous carcinoma
Group #case Mean IMP3 signa
age (Total#)
LR 196 48.6 25
HR 60 46.2 226
PSC 60 61.5 184
HR: high-risk; STIC: serous tubal intraepithelial carcinoma; PSC: pelvic serous carcino
patients with high-risk (9.04-fold) and those with PSC (7.36-fold) than that in contropositive cases regardless of the number of foci of lesions
found in a single case. Overall, the frequency of IMP3-SCE
(82%) was more prevalent than IMP3-SCOUTs (18%) in
both high-risk and PSC groups. The absolute frequency of
STIC in tubal fimbria in the three groups was 0% (0/196),
15% (9/60), and 32% (19/60). The STIC data are com-
parable to previous findings [32,33]. Among the 9 STIC
cases in high-risk group, strong cytoplasmic IMP3 staining
(appearing in more than 50% of the neoplastic cells) was
found in 5 (55%) cases; similarly, among the 19 STIC
cases in PSC group, 11 (58%) were found with strong
IMP3 staining. Furthermore, the positive IMP3 expression
was found in 38 (63%) of 60 PSC cases. Interestingly, all
11 STIC cases in PSC group with positive IMP3 were also
positive for IMP3 in the corresponding invasive cancerexpression in serous tubal intraepithelial carcinoma and
tures STIC PSC
#of + cases/HR (%) #of + cases (%)
0 (0) 0 (0)
5/9 (55) 0 (0)
11/19 (58) 38 (63)
ma. The frequency of IMP3 signatures was much higher in tubal fimbria of
l group (p < 0.0001).
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located in the areas mostly adjacent to the areas of STIC.
Representative pictures of IMP3 signatures and IMP3
overexpression in STIC as well as in PSC are illustrated in
Figure 3.
Discussion
In this study, we have examined IMP3 signature and its
relationship with the aging process in patients with low-
risk, high-risk, and PSC. For patients in the low-risk of
PSC (control group), IMP3 signatures increased from 0
in patients <50 years of age to 11 in patients >70 years
of age. The IMP3 signatures steadily increased with age,
which is consistent to well-known epidemiologic findings
that PSC increases with age and shows a peak incidence
after menopause [17,35,36]. A more prominent increase of
IMP3 signatures is observed in patients with high-risk
factors, such as BRCA mutations or first degree family
history of ovarian cancer, and in patients with PSC. In-
creased IMP3 signatures are also closely associated with
age in both high-risk and PSC patients’ groups. Import-
antly, we found that age alone seems an independent risk
factor, although it is less dramatic than the likely genetic
alterations affecting high-risk and PSC populations, which
have been well demonstrated in other studies [2,37,38].
As approximately 90% of women’s pelvic serous cancers
including tubal, ovarian, and peritoneal origins are spor-
adic without identifiable genetic reasons [39], aging alone
may play a role in serous neoplasia. Future studies ad-
dressing the connection between aging and pelvic serous
neoplasia are needed to shed light on potential preventive
strategies.
Tubal epithelia contain two distinctive cell types: secretory
and ciliated cells. It is believed that tubal secretory cells
represent the cell of origin for the majority PSCs in
women. After we identified the phenomenon of IMP3 sig-
natures in tubal epithelia, we further verified that IMP3Figure 3 IMP3 overexpression in tubal serous tubal intraepithelial car
arrow, right) shows morphologically bland cells (single arrow, left), which e
(double arrows). The IMP3 is also diffusely positive in the invasive compone
to the tubal fimbria in a case with PSC.staining is also mainly localized in the tubal secretory cells
rather than in the ciliated cells. The current model for the
pelvic serous carcinogenesis starts from the expansion of
secretory cells and the loss of tubal ciliated cells, which re-
sult in morphologically identifiable SCE and/or SCOUTs.
These expanded segments of secretory cells are usually
distributed evenly within the tubal fimbria and ampulla
segments. In this study, however, we found that IMP3
signatures (tubal secretory cells positive for IMP3) are
about 10-fold more frequent in tubal fimbria than that in
the ampulla region (p < 0.001). Assuming all the secretory
cells are equally susceptible to serous neoplasia, the fre-
quency of serous STIC or early invasive carcinoma should
be equally distributed in those tubal regions. However,
many studies in the last decade revealed that majority
STICs with or without early invasions are located in the
tubal fimbria, while only a small percentage are in the
tubal ampulla [16,40-42]. This is supportive of previous
observations that the fimbriae are the main site of origin
for the serous neoplasia. It is currently unclear what the
exact underlying molecular mechanism is for tubal fimbria
serving as the most vulnerable segment to develop serous
cancers. Apparently, regulatory factors of the cell cycle
may be involved in this process. Alteration of TP53 in-
cluding p53 signatures has been recognized as an important
initial stage for the development of PSC. Tubal epithelia
with p53 signatures are favoured as latent precancer cells
of PSC and they are also more frequently located in tubal
fimbria [5,16]. Our finding of IMP3 signatures being more
prevalent in tubal fimbria may represent an additional
important biomarker for serous cancer development. The
relationship between the TP53 and IMP3 in the process
of tubal serous carcinogenesis is under active study in
our laboratory.
Both SCEs and SCOUTs have been considered as valid
biomarkers for PSC since they are linked to serous neo-
plasia [7,8,13,15,43]. In this study, we showed that thecinoma and invasive serous carcinoma. IMP3 signatures (single
xists in anatomic continuity with tubal serous intraepithelial carcinoma
nt of the serous carcinoma (triple arrows), which is located adjacent
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SCOUTs in all patients studied, which supports the recent
findings that SCE is more sensitive than SCOUTs in asso-
ciation with serous neoplasia [15]. Since IMP3 staining is
easily performed and the IMP3 signatures are readily iden-
tifiable under routine microscopy, it can serve as an add-
itional biomarker in the process of serous carcinogenesis.
Tubal secretory cells with IMP3 overexpression likely have
growth advantage over secretory cells without IMP3 over-
expression or ciliated cells. Such growth advantage may
offer them a better opportunity to grow and evolve into
PSC. However, the predictive value of IMP3 signatures for
the PSC development needs to be further studied and vali-
dated prior to its clinical application.
In addition to the IMP3 overexpression in benign-
appearing tubal epithelia, IMP3 is also overexpressed
in 55% of STIC cases in high-risk patients, 58% of STIC
cases in PSC and in 63% PSC cases. More interestingly,
many IMP3 signatures were demonstrated to exist in
anatomic continuity with STIC, suggesting a step-wise
development from IMP3 signatures to STIC, then to PSC
and further supporting that overexpression of IMP3 may
be involved in the initial process of tubal or pelvic serous
carcinogenesis.
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